STAT

Opinion: After amyloid failures, it’s time to take a new tack for treating Alzheimer’s

The amyloid cabal and groupthink kept other ideas for #Alzheimers treatments from being developed. Now that the insanity of that approach is behind us, it's time to make real progress…

If insanity is doing the same thing over and over again but expecting different results, then the last decade or so of Alzheimer’s disease drug development has been insane. Three carefully designed, well-executed, and fully resourced trials targeting amyloid protein in the brain as the cause of Alzheimer’s disease have failed. It’s long past time to take a new approach to this mind-robbing disease.

In 1906, psychiatrist Alois Alzheimer of a 50-year-old woman he had followed for five years, from her admission to a psychiatric hospital for paranoia, progressive sleep and memory disturbance, aggression, and confusion until her death. His autopsy of her brain revealed unusual plaques of amyloid and tangles of neurofibrils. Three years later he described three more cases, including one individual whose brain showed only

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readWellness
New Evidence Points To Possible Cause Of Puzzling Paralysis In Kids
Researchers say they have strong new evidence that a virus is involved in a rare and puzzling polio-like condition affecting U.S. children.
STAT3 min readSociety
Health Officials Ramp Up Ebola Response After First Cases Reported In Uganda
The 5-year-old boy who was infected with Ebola and crossed into Uganda earlier this week has died, the country’s health ministry said Wednesday.
STAT1 min read
Listen: Biohacking Meets Bureaucracy, And The Latest Twist In CRISPR World
Is biohacking a crime? And who came up with the latest #CRISPR trick? Find out on the latest episode of our #biotech #podcast, "The Readout LOUD." Listen now: